Apr. 6, 2016
On April 6, 2016 Abpro, an integrated life science company at the forefront of synthetic biology, announced its partnership with Essex Bio, a China-based biopharmaceutical company. Abpro and Essex will co-develop multiple monoclonal antibodies in immuno-oncology and ophthalmology by leveraging Abpro’s DiversImmune™ platform.
In the context of the transaction, Abpro received a $3.5M equity investment from Essex Bio and an undisclosed amount from affiliates.